GSK256073 acutely regulates NEFA levels via HCA2 agonism but does not achieve durable glycaemic control in type 2 diabetes. A randomised trial

European Journal of Pharmacology

Volumn 755, Issue , 2015, Pages 95-101

  Dobbins, Robert ^a   Byerly, Robert ^a   Gaddy, Riley ^a   Gao, Feng ^a   Mahar, Kelly ^a   Napolitano, Antonella ^b   Ambery, Philip ^c   Le Monnier De Gouville, Anne Charlotte ^d  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d GLAXOSMITHKLINE   (France)

Author keywords

GSK 256073; HbA1c; Non Esterified Fatty Acid(NEFA) Hydroxy carboxylicacidreceptor2(HCA2); Type 2diabetes

Indexed keywords

ANTIDIABETIC AGENT; FATTY ACID; FRUCTOSAMINE; GLUCOSE; GSK 256073; HEMOGLOBIN; HEMOGLOBIN A1C; HYDROXYCARBOXYLIC ACID RECEPTOR 2; INSULIN; METFORMIN; PLACEBO; RECEPTOR; UNCLASSIFIED DRUG; URIC ACID; 8-CHLORO-3-PENTYL-1H-PURINE-2,6(3H,7H)-DIONE; G PROTEIN COUPLED RECEPTOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HCAR2 PROTEIN, HUMAN; HEMOGLOBIN A1C PROTEIN, HUMAN; NICOTINIC RECEPTOR; XANTHINE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASSESSMENT OF HUMANS; ASTHENIA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG RELATED FLUSHING; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE OXIDATION; GLYCEMIC CONTROL; HEART ATRIUM FIBRILLATION; HEMOGLOBIN BLOOD LEVEL; HOMOEOSTASIS ASSESSMENT INDEX; HUMAN; IN VITRO STUDY; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE COUNT; SIDE EFFECT; SKIN TINGLING; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; URIC ACID BLOOD LEVEL; AGED; AGONISTS; ANALYSIS; BLOOD; DIABETES MELLITUS, TYPE 2; TREATMENT OUTCOME;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FATTY ACIDS, NONESTERIFIED; FEMALE; FRUCTOSAMINE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; MALE; MIDDLE AGED; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NICOTINIC; TREATMENT OUTCOME; XANTHINES;

EID: 84925448638     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2015.03.005     Document Type: Article

References (22)

1. M. Bajaj, S. Suraamornkul, A. Romanelli, G.W. Cline, L.J. Mandarino, and G.I. Shulman Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients Diabetes 54 2005 3148 3153
2. S.E. Baldeweg, A. Golay, A. Natali, B. Balkau, S. del Prato, and S.W. Coppack Insulin resistance, lipid and fatty acid concentrations in 867 healthy Europeans Eur. J. Clin. Investig. 30 2000 45 52
3. R.L. Dobbins, S.P. Shearn, R.L. Byerly, F.F. Gao, K.M. Mahar, and A. Napolitano GSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus Diab. Obes. Metab. 15 2013 1013 1021
4. A. Garg, and S.M. Grundy Nicotinic acid as therapy for dyslipidemia in noninsulin-dependent diabetes mellitus J. Am. Med. Assoc. 264 1990 723 726
5. A Girousse, G. Tavernier, C. Valle, C. Moro, N. Mejhert, and A.-L. Dinel Partial inhibition of adipose tissue lipolysis improves glucose metabolism and insulin sensitivity without alteration of fat mass PLoS Biol. 11 2013 e1001485 10.1371/journal.pbio.1001485
6. S.M. Grundy, G.L. Vega, M.E. McGovern, B.R. Tulloch, D.M. Kendall, and D. Fitz-Patrick Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial Arch. Intern. Med. 162 2002 1568 1576
7. B. Lauring, A.K. Taggart, J.R. Tata, R. Dunbar, L. Caro, and K. Cheng Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression Sci. Transl. Med. 4 2012 148ra115
8. M. Lavezzari, G. Milanesi, E. Oggioni, and F. Pamparana Results of a phase IV study carried out with Acipimox in type II diabetic patients with concomitant hyperlipoproteinaemia J. Int. Med. Res. 17 1989 373380
9. D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, DF Treacher, and R.C. Turner Homoeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412 419
10. J.D. McGarry Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes Diabetes 51 2002 7 18
11. V. Mohan, W. Yang, H.Y. Son, L. Xu, L. Noble, and R.B. Landon Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea Diab. Res. Clin. Pract. 83 2009 106 116
12. G. Paolisso, P.A. Tataranni, J.E. Foley, C. Bogardus, B.V. Howard, and E. Ravussin A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM Diabetologia 38 1995 1213 1217
13. P.J. Randle, P.B. Garland, C.N. Hales, and E.A. Newholme The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus Lancet 1 1963 785 789
14. G.M. Reaven, C. Hollenbeck, C.Y. Jeng, M.S. Wu, and Y.D. Chen Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM Diabetes 37 1988 1020 1024
15. M. Roden, H. Stingl, V. Chandramouli, W.C. Schumann, A. Hofer, and B.R. Landau Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans Diabetes 49 2000 701 707
16. C. Saloranta, L. Groop, A. Ekstrand, A. Franssila-Kallunki, J. Eriksson, and M.R. Taskinen Different acute and chronic effects of acipimox treatment on glucose and lipid metabolism in patients with type 2 diabetes Diab. Med. 10 1993 950 957
17. C. Saloranta, M.R. Taskinen, E. Widen, M. Harkonen, A. Melander, and L. Groop Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM Diabetes 42 1993 1559 1566
18. Boden G. Santomauro ATMG, M.E.R. Silva, D.M. Rocha, R.F. Santos, and M.J.M. Ursich Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and non diabetic subjects Diabetes 48 1999 1836 1841
19. G.I. Shulman Cellular mechanism of insulin resistance J. Clin. Investig. 106 2000 171 176
20. A.A. Vaag, and H. Beck-Nielsen Effects of prolonged Acipimox treatment on glucose and lipid metabolism and on in vivo insulin sensitivity in patients with non-insulin dependent diabetes mellitus Acta Endocrinol. 127 1992 344 350
21. H. Vosper Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia Br. J. Pharmacol. 158 2009 429 441
22. D. Worm, J.E. Henricksen, A. Vaag, P. Thye-Rønn, A. Melander, and H. Beck-Nieldsen Pronounced blood glucose-lowering effect of the antilipolytic drug Acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period J. Clin. Endocrinol. Metab. 78 1994 717 721